AbbVie (NYSE:ABBV) Earns Neutral Rating from Citigroup
Citigroup reissued their neutral rating on shares of AbbVie (NYSE:ABBV – Free Report) in a research note published on Wednesday morning, MarketBeat reports. They currently have a $205.00 target price on the stock, down from their previous target price of $210.00. Other analysts also recently issued research reports about the stock. The Goldman Sachs Group […]
Citigroup reissued their neutral rating on shares of AbbVie (NYSE:ABBV – Free Report) in a research note published on Wednesday morning, MarketBeat reports. They currently have a $205.00 target price on the stock, down from their previous target price of $210.00. Other analysts also recently issued research reports about the stock. The Goldman Sachs Group […]
